|
| 生长抑素治疗急性胰腺炎的药物经济学研究 |
| Pharmacoeconomic Analysis of Somatostatin in the Treatment of Acute Pancreatitis |
| 投稿时间：2012-07-30 修订日期：2012-09-28 |
| DOI： |
| 中文关键词: 生长抑素 急性胰腺炎 药物经济学 最小成本分析法 |
| 英文关键词:Somatostatin Acute pancreatitis Pharmacoeconomic analysis Cost minimization analysis |
| 基金项目:无锡市药师协会——常州四药临床药学科研基金（编号：CSZ00N1139） |
|
| 摘要点击次数: 2127 |
| 全文下载次数: 1594 |
| 中文摘要: |
| 摘 要 目的：探讨国产、进口生长抑素治疗急性胰腺炎的经济效果。方法：选择42例急性胰腺炎发作患者，按疾病分型随机分为两组，分别用国产和进口的生长抑素治疗，运用药物经济学的最小成本分析进行评价。结果：国产组、进口组有效率分别为90.91%、95.00%（P>0.05），平均成本分别为1 451.96元、7 027.30元（P<0.05）；两组均无不良反应发生。结论：从药物经济学最小成本法的角度分析，利用国产生长抑素治疗急性胰腺炎方案较佳。 |
| 英文摘要: |
| ABSTRACT Objective:To evaluate the economic effects of domestic somatostatin vs. imported somatostatin for acute pancreatitis. Methods:42 patients with acute pancreatitis were randomly divided into 2 groups treated with domestic somatostatin and imported somatostatin and evaluated with the cost minimization analysis. Methods:The effective rates of the two groups (domestic somatostatin, imported somatostatin) were 90.91% and 95.00%, respectively(P>0.05). Average costs were 1 451.96yuan and 7 027.30 yuan, respectively (P<0.05). Meanwhile, no adverse reactions occurred. Conclusion:From cost minimization analysis, the domestic somatostatin group scheme was better. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
